JMJD2A promotes the development of castration‐resistant prostate cancer by activating androgen receptor enhancer and inhibiting the cGAS‐STING pathway
Molecular Carcinogenesis · 2024
DOI: 10.1002/mc.23753 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Carcinogenesis, 2024. Verfasst von Xiang Cai und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Receptors, Androgen, Jumonji Domain-Containing Histone Demethylases, Signal Transduction. Die Arbeit wurde bisher 13-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Primary Health Development Research Center of Sichuan Province Program, Application and Basic Research Program of Sichuan Science and Technology Department, City of Nanchong Strategic Cooperation with Local Universities Foundation of technology.
Abstract (Originalsprache)
Exploring targets for inhibiting androgen receptor (AR) activity is an effective strategy for suppressing the development of castration‐resistant prostate cancer (CRPC). Upregulation of histone demethylase JMJD2A activity is an important factor in increasing AR expression in CRPC. Based on our research, we found that the binding affinity between JMJD2A and AR increases in CRPC, while the level of AR histone methylation decreases and the H3K27ac level increases in the AR enhancer region. Further investigations revealed that overexpression of the histone demethylase JMJD2A increased the binding affinity between JMJD2A and AR, decreased AR histone methylation levels, upregulated H3K27ac in the AR enhancer region, and increased AR activity. Conversely, knocking down JMJD2A effectively reversed these effects. Additionally, in CRPC, JMJD2A expression was upregulated, the tumor‐intrinsic immune cGAS‐STING signaling pathway was suppressed, the tumor microenvironment was altered, and AR expression was upregulated. However, both knocking down JMJD2A and inhibiting the cyclic GMP‐AMP synthase/stimulator of interferon genes (cGAS‐STING) signaling pathway reversed these effects. In summary, our study indicates that in CRPC, JMJD2A can directly bind to AR and activate residual AR enhancers through its demethylation activity, thereby promoting AR expression. Furthermore, upregulation of JMJD2A expression inhibits the innate immune cGAS‐STING signaling pathway of the tumor, leading to a decrease in antitumor immune function, and further promoting AR expression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, China.
- Department of Pharmacy, First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Förderung
- Primary Health Development Research Center of Sichuan Province Program
- Application and Basic Research Program of Sichuan Science and Technology Department
- City of Nanchong Strategic Cooperation with Local Universities Foundation of technology
- Medical Research project of Sichuan Medical Association
Zitieren
APA
Cai, X., Yu, X., Tang, T., Xu, Y., & Wu, T. (2024). JMJD2A promotes the development of castration‐resistant prostate cancer by activating androgen receptor enhancer and inhibiting the cGAS‐STING pathway. Molecular Carcinogenesis. https://doi.org/10.1002/mc.23753
Vancouver
Cai X, Yu X, Tang T, Xu Y, Wu T. JMJD2A promotes the development of castration‐resistant prostate cancer by activating androgen receptor enhancer and inhibiting the cGAS‐STING pathway. Molecular Carcinogenesis. 2024. doi:10.1002/mc.23753
BibTeX
@article{Cai2024,
author = {Cai, Xiang and Yu, Xiaodong and Tang, Tielong and Xu, Yi and Wu, Tao},
title = {JMJD2A promotes the development of castration‐resistant prostate cancer by activating androgen receptor enhancer and inhibiting the cGAS‐STING pathway},
journal = {Molecular Carcinogenesis},
year = {2024},
doi = {10.1002/mc.23753}
}
EUVIMED